As oncologists and the healthcare industry advance their practices to propel care for children, it is crucial for the industry and population at large to tailor care for the unique needs of children to maximize recovery and truly help patients thrive.
The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.
A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.
R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 trial for cancer treatment.
An abstract is unavailable.
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Yang et al. report that the intracellular CD28 in triple negative breast cancer (TNBC) cells promotes PD-L1-mediated immune escape. Inhibition of CD28 in cancer cells decreases…
More men with limited life expectancy and certain localized prostate cancers have received definitive treatment over the past 2 decades despite shifts toward active surveillance,…
Neelima Vidula, MD, Massachusetts General Hospital, Boston, MA, comments a retrospective analysis of organ site-specific responses to sacituzumab govitecan and trastuzumab deruxtecan in metastatic breast…
Adding a PD-1 antibody to BCG led to improved event-free survival in patients with non–muscle invasive bladder cancer.
James K. McCloskey, MD, and Harry P. Erba, MD, PhD, discuss the diagnosis and prevalence of secondary acute myeloid leukemia.
